Ono Pharmaceutical Co Ltd (OPHLY)
4.542
-0.01
(-0.18%)
USD |
OTCM |
Jul 01, 15:59
Ono Pharmaceutical Revenue (Quarterly): 759.81M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 759.81M |
| December 31, 2023 | 888.51M |
| September 30, 2023 | 960.20M |
| June 30, 2023 | 874.63M |
| March 31, 2023 | 818.91M |
| December 31, 2022 | 867.63M |
| September 30, 2022 | 796.12M |
| June 30, 2022 | 823.64M |
| March 31, 2022 | 774.11M |
| December 31, 2021 | 856.40M |
| September 30, 2021 | 787.82M |
| June 30, 2021 | 798.14M |
| March 31, 2021 | 702.02M |
| December 31, 2020 | 808.68M |
| September 30, 2020 | 711.97M |
| June 30, 2020 | 696.16M |
| March 31, 2020 | 616.33M |
| December 31, 2019 | 701.60M |
| September 30, 2019 | 699.48M |
| June 30, 2019 | 673.12M |
| March 31, 2019 | 594.22M |
| December 31, 2018 | 698.97M |
| September 30, 2018 | 656.32M |
| June 30, 2018 | 653.18M |
| March 31, 2018 | 565.19M |
| Date | Value |
|---|---|
| December 31, 2017 | 700.60M |
| September 30, 2017 | 545.75M |
| June 30, 2017 | 548.24M |
| March 31, 2017 | 492.07M |
| December 31, 2016 | 651.70M |
| September 30, 2016 | 576.13M |
| June 30, 2016 | 544.03M |
| March 31, 2016 | 415.42M |
| December 31, 2015 | 346.71M |
| September 30, 2015 | 283.26M |
| June 30, 2015 | 294.27M |
| March 31, 2015 | 239.26M |
| December 31, 2014 | 392.49M |
| September 30, 2014 | 294.15M |
| June 30, 2014 | 311.37M |
| March 31, 2014 | 309.37M |
| December 31, 2013 | 405.11M |
| September 30, 2013 | 338.23M |
| June 30, 2013 | 377.68M |
| March 31, 2013 | 330.50M |
| December 31, 2012 | 508.11M |
| September 30, 2012 | 425.50M |
| June 30, 2012 | 469.72M |
| March 31, 2012 | 416.47M |
| December 31, 2011 | 550.68M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
616.33M
Minimum
Mar 2020
960.20M
Maximum
Sep 2023
786.43M
Average
796.12M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 7.081B |
| Nxera Pharma Co Ltd | 31.07M |
| PeptiDream Inc | 28.47M |
| Healios KK | 0.0674M |
| AnGes Inc | 0.7651M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 117.46M |
| Total Expenses (Quarterly) | 656.66M |
| EPS Diluted (Quarterly) | 0.0842 |
| Enterprise Value | 5.097B |
| Gross Profit Margin (Quarterly) | 71.92% |
| Profit Margin (Quarterly) | 15.46% |
| Earnings Yield | 13.58% |
| Operating Earnings Yield | 17.00% |
| Normalized Earnings Yield | 13.58 |